Treatment options for patients with coronary microvascular dysfunction - EuroPCR 2025

Coronary microvascular dysfunction (CMD) is an important cause of angina and dyspnea, even in the absence of obstructive coronary artery disease (CAD). This #europcr 2025 session explains how physiology testing in the cathlab can identify distinct CMD endotypes and why exercise treadmill testing (ETT) may not be reliable for patients with symptoms at rest. Discover the latest A-FLUX coronary sinus reducer system, featuring an improved design aimed at simplifying the procedure and enhancing symptom relief by reducing microvascular resistance. Early data suggest this therapy is safe, simple, and effective, with further clinical evidence expected from the upcoming SERRA-I early feasibility study. Gain key insights into the diagnosis and evolving treatment options for CMD patients experiencing persistent angina or angina-like symptoms. Sponsored by VahatiCor More videos on PCRonline: https://www.pcronline.com/Cases-resou... #cmd, #coronarymicrovasculardysfunction, #angina, #dyspnea, #cad, #ett, #coronarysinusreducer, #physiology